Clinical trial
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue…
NCT00147316 · Tanabe Pharma Corporation, Industry · Completed
Key facts
| NCT number | NCT00147316 |
|---|---|
| Title | Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke |
| Official title | Japan Alteplase Clinical Trial (J-ACT): Phase 3 Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Acute Ischemic Stroke Within 3 Hours of Onset |
| Lead sponsor | Tanabe Pharma Corporation, Industry |
| Collaborators | Kyowa Hakko Kogyo Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cerebral Infarction, Brain Ischemia |
| Intervention type | Drug |
| Interventions | Alteplase |
| Enrollment | 103 |
| Start date | Apr 1, 2002 |
| Completion | Sep 1, 2003 |
| First posted | Sep 7, 2005 |
| Last update posted | Jan 5, 2026 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: